DRG Epidemiology’s coverage of HIV/AIDS-related neuropathy comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of HIV/AIDS-related neuropathy for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s HIV/AIDS-related neuropathy forecast will answer the following questions:
Of all people with HIV/AIDS-related neuropathy, how many in each major mature pharmaceutical market experience NP?
Of all people with HIV/AIDS-related NP, how many in each major mature pharmaceutical market have been formally diagnosed?
Of all people diagnosed with HIV/AIDS-related NP, how many in each major mature pharmaceutical market are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HIV/AIDS-related neuropathy over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following HIV/AIDS-related neuropathy subpopulations:
Total prevalent cases of HIV/AIDS-related NP.
Diagnosed prevalent cases of HIV/AIDS-related NP.
Drug-treated prevalent cases of HIV/AIDS-related NP.
Prevalence of HIV/AIDS-Related Neuropathy per 1,000 People of All Ages in 2021 and 2031
Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of HIV/AIDS-Related Neuropathy Over the Next 10 Years
Analysis of the Prevalent Cases of HIV/AIDS-Related Neuropathy in 2021 by Neuropathic Pain
Analysis of the Prevalent Cases of HIV/AIDS-Related Neuropathy in 2021 by Neuropathic Pain
Analysis of the Prevalent Cases of HIV/AIDS-Related Neuropathy in 2021 by Diagnosed and Drug-Treated Status
Number of Additional Prevalent Cases of HIV/AIDS-Related Neuropathy in 2031 in the Countries Under Study due to Trends in Survival
Epidemiology Data
Methods
Total Prevalence of HIV/AIDS-Related Neuropathy
Total Prevalence of HIV/AIDS-Related Neuropathic Pain
Diagnosed Prevalence of HIV/AIDS-Related Neuropathic Pain
Percentage Drug-Treated
Reference Materials
Literature Review
Studies Included in the Analysis of HIV/AIDS-Related Neuropathy
Studies Excluded from the Analysis of HIV/AIDS-Related Neuropathy
Risk/Protective Factors
Risk/Protective Factors for HIV/AIDS-Related Neuropathy
Bibliography
Glossary
Sunali D. Goonesekera, S.M.
Sunali Goonesekera, S.M., is a senior epidemiologist at Clarivate. Previously, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.
